J T Brandt

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation
    John T Brandt
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Am Heart J 153:66.e9-16. 2007
  2. doi Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects
    Christopher D Payne
    Lilly Research Laboratories, Eli Lilly and Company, Windlesham, Surrey, UK
    Platelets 19:275-81. 2008
  3. doi The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration
    Joseph A Jakubowski
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Thromb Haemost 99:409-15. 2008
  4. doi Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
    David S Small
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center DC 0724, Indianapolis, IN 46285, USA
    J Clin Pharmacol 48:475-84. 2008
  5. doi Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects
    Nagy A Farid
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Pharmacotherapy 28:1483-94. 2008
  6. ncbi Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
    J T Brandt
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Thromb Haemost 5:2429-36. 2007
  7. ncbi Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently
    N A Farid
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
    Clin Pharmacol Ther 81:735-41. 2007
  8. doi Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects
    N A Farid
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 6285, USA
    Curr Med Res Opin 25:1821-9. 2009
  9. doi Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease
    D S Small
    Eli Lilly and Company, Indianapolis, IN, USA
    J Clin Pharm Ther 34:585-94. 2009
  10. ncbi Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel
    Christopher D Payne
    Lilly Research Laboratories, Eli Lilly and Company, Windlesham, Surrey, UK
    J Cardiovasc Pharmacol 50:555-62. 2007

Collaborators

Detail Information

Publications30

  1. ncbi A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation
    John T Brandt
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Am Heart J 153:66.e9-16. 2007
    ..Thienopyridines are prodrugs, metabolized in vivo to active metabolites that inhibit the platelet P2Y12 adenosine diphosphate (ADP) receptor...
  2. doi Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects
    Christopher D Payne
    Lilly Research Laboratories, Eli Lilly and Company, Windlesham, Surrey, UK
    Platelets 19:275-81. 2008
    ..Switching directly from clopidogrel MD to either prasugrel LD or MD was well tolerated and resulted in significantly greater levels of platelet inhibition than a clopidogrel 75 mg MD...
  3. doi The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration
    Joseph A Jakubowski
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Thromb Haemost 99:409-15. 2008
    ..The determination of the clinical utility of such POC devices will require their use in clinical outcome studies...
  4. doi Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
    David S Small
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center DC 0724, Indianapolis, IN 46285, USA
    J Clin Pharmacol 48:475-84. 2008
    ..The overall data suggest that a prasugrel dose adjustment is not likely warranted in an individual taking prasugrel with a proton pump inhibitor such as lansoprazole...
  5. doi Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects
    Nagy A Farid
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Pharmacotherapy 28:1483-94. 2008
    ..To investigate the potential effect of atorvastatin 80 mg/day on the pharmacokinetics and pharmacodynamics of the thienopyridines prasugrel and clopidogrel...
  6. ncbi Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
    J T Brandt
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Thromb Haemost 5:2429-36. 2007
    ..The pharmacodynamic response to clopidogrel is more variable than the response to prasugrel, but the reasons for variation in response to clopidogrel are not well characterized...
  7. ncbi Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently
    N A Farid
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
    Clin Pharmacol Ther 81:735-41. 2007
    ..We conclude that CYP3A4 and CYP3A5 inhibition by ketoconazole affects formation of clopidogrel's but not prasugrel's active metabolite. The decreased formation of clopidogrel's active metabolite is associated with reduced IPA...
  8. doi Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects
    N A Farid
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 6285, USA
    Curr Med Res Opin 25:1821-9. 2009
    ....
  9. doi Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease
    D S Small
    Eli Lilly and Company, Indianapolis, IN, USA
    J Clin Pharm Ther 34:585-94. 2009
    ..The pharmacokinetic (PK) and pharmacodynamic (PD) responses to prasugrel were compared in three studies of healthy subjects vs. those with moderate or end-stage renal impairment...
  10. ncbi Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel
    Christopher D Payne
    Lilly Research Laboratories, Eli Lilly and Company, Windlesham, Surrey, UK
    J Cardiovasc Pharmacol 50:555-62. 2007
    ..In conclusion, greater exposure to prasugrel's active metabolite results in faster onset, higher levels, and less variability of platelet inhibition compared with high-dose clopidogrel in healthy subjects...
  11. doi Evaluation of anti-activated protein C antibody development in patients with severe sepsis from four clinical studies with drotrecogin alpha (activated)
    S B Yan
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Thromb Haemost 7:1787-94. 2009
    ..Drotrecogin alpha (activated) (DAA) is a recombinant human activated protein C (APC), which is an antithrombotic protein. Objectives: To evaluate the development of anti-APC antibodies in severe sepsis patients in DAA clinical studies...
  12. ncbi Urinary desmosine as a biomarker in acute lung injury
    J A Fill
    Eli Lilly and Co, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Biomarkers 11:85-96. 2006
    ..Hydrolysis of urine samples appears necessary for optimal measurement of urine desmosine...
  13. ncbi Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis
    Govinda J Weerakkody
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Cardiovasc Pharmacol Ther 12:205-12. 2007
    ..Regardless of the criterion, prasugrel 60 mg achieved greater IPA and fewer poor responders than the clopidogrel 300-mg LD...
  14. ncbi Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status
    Govinda J Weerakkody
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
    Am J Cardiol 100:331-6. 2007
    ..After a thienopyridine LD, the initial rate of platelet inhibition was predictive of pharmacodynamic responder status...
  15. doi A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry
    Joseph A Jakubowski
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Thromb Haemost 99:215-22. 2008
    ..86, p < 0.0001). VASP and LTA demonstrated concordance across the response range of P2Y(12) receptor blockade following thienopyridine LDs...
  16. ncbi Clopidogrel poor responders: an objective definition based on Bayesian classification
    Govinda J Weerakkody
    Lilly Research Laboratories, Eli Lilly and Co, Lilly Corporate Center, Indianapolis, IN, 46285, USA
    Platelets 18:428-35. 2007
    ..Objective thresholds for pharmacodynamic poor responders to clopidogrel should consider the concentration of the agonist used and may help assess the consistency of pharmacodynamic response to novel ADP receptor antagonists...
  17. ncbi Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects
    Joseph A Jakubowski
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Cardiovasc Pharmacol 49:167-73. 2007
    ..Within the limitations of the study, prasugrel was found to be well tolerated when dosed as LD followed by MD in the presence of ASA and provided greater platelet inhibition than ASA alone...
  18. pmc A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans
    Joseph A Jakubowski
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Br J Clin Pharmacol 63:421-30. 2007
    ....
  19. doi Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects
    Ying G Li
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Platelets 20:316-27. 2009
    ..Gender, race, body weight, and age were identified as statistically significant covariates impacting platelet inhibition...
  20. ncbi The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects
    Joseph A Jakubowski
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Cardiovasc Pharmacol 47:377-84. 2006
    ..Prasugrel LDs and MDs provide rapid and sustained inhibition of ADP-mediated platelet aggregation...
  21. ncbi Differential reactivity of anti-primate and anti-human secondary antibodies against human and monkey immunoglobulins: implications for determining the sensitivity of immunogenicity assays
    James S Bourdage
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, United States
    J Immunol Methods 303:76-80. 2005
    ..As a result, the use of affinity purified primate antibodies to determine the sensitivity of an immunogenicity assay will likely result in the true sensitivity of the assay being underestimated...
  22. ncbi Effect of double antigen bridging immunoassay format on antigen coating concentration dependence and implications for designing immunogenicity assays for monoclonal antibodies
    James S Bourdage
    Lilly Research Laboratories, Eli Lilly and Company, Building 88 313, Eli Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Pharm Biomed Anal 39:685-90. 2005
    ..Together, these findings indicate that a one-step assay format can greatly reduce the effect of coating concentration variation on assay performance...
  23. ncbi Development, validation, and implementation of a multiplex immunoassay for the simultaneous determination of five cytokines in human serum
    Chad A Ray
    Laboratory for Experimental Medicine, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Pharm Biomed Anal 36:1037-44. 2005
    ..Efficient use of this platform requires process improvements to fully maximize the positive impact of multiplex assays in clinical drug development...
  24. ncbi Plasminogen and tissue-type plasminogen activator deficiency as risk factors for thromboembolic disease
    John T Brandt
    Eli Lilly and Co, Lilly Corporate Center, Indianapolis, Ind 46285, USA
    Arch Pathol Lab Med 126:1376-81. 2002
    ..To review the published evidence for an association between a deficiency of plasminogen or tissue-type plasminogen activator (tPA) and the risk of thrombosis...
  25. ncbi Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a multiple-dose study in healthy humans
    Nobuko Matsushima
    Sankyo Co, Ltd, Tokyo, Japan
    Platelets 17:218-26. 2006
    ..This study indicated that prasugrel 10 mg daily for 10 days was well tolerated and at steady-state provided sustained high levels of inhibition of platelet aggregation...
  26. ncbi Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans
    Fumitoshi Asai
    Sankyo Co, Ltd, Tokyo, Japan
    Platelets 17:209-17. 2006
    ..In conclusion, prasugrel 30 and 75 mg were well tolerated and achieved a consistently high level of platelet inhibition with a fast onset of action...
  27. ncbi Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease
    Tomas Jernberg
    Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, University Hospital, 751 85 Uppsala, Sweden
    Eur Heart J 27:1166-73. 2006
    ..This study was designed to compare the degree of inhibition of platelet aggregation (IPA) of prasugrel with that of clopidogrel in stable aspirin-treated patients with coronary artery disease (CAD)...
  28. ncbi Effect of fondaparinux on coagulation assays: results of College of American Pathologists proficiency testing
    Agata Smogorzewska
    Department of Pathology and Laboratory Medicine, Harvard Medical School, Massachusetts General Hospital, Boston 02114, USA
    Arch Pathol Lab Med 130:1605-11. 2006
    ..It may also be efficacious, safe, and cost-effective for other patients; thus, more widespread use of fondaparinux is likely. The effect of fondaparinux on coagulation testing needs to be thoroughly examined...
  29. ncbi External peer review quality assurance testing in von Willebrand disease: the recent experience of the United States College of American Pathologists proficiency testing program
    Timothy E Hayes
    Department of Pathology and Laboratory Medicine, Maine Medical Center, Portland, Maine 04102, USA
    Semin Thromb Hemost 32:499-504. 2006
    ..3 to 30.9%). The reference materials used in the standard curves for immunoturbidometric vWF:Ag assays appear to have accurately assigned vWF values for the majority of commercial suppliers...
  30. ncbi Quality assurance in hemostasis: the perspective from the College of American Pathologists proficiency testing program
    Mark T Cunningham
    Department of Pathology, University of Kansas Medical Center, Kansas City, Kansas 66160, USA
    Semin Thromb Hemost 33:250-8. 2007
    ....